Kinetic evidence for the presence of two prostaglandin receptor sites regulating the activity of intestinal adenylate cyclase sensitive to Escherichia coli enterotoxin.
Kinetic behavior most consistent with the presence of two independent, but simultaneously acting, regulatory effector sites for prostaglandins has been presented for adenylate cyclase (EC 4.6.1.1) of rabbit intestinal epithelial cells. One site regulates activation of the catalytic site, while the other site regulates inhibition. A synthetic prostaglandin analogue, 7-oxa-13-prostynoic acid, is recognized at both sites in a concentration-dependent manner. At concentrations of 7-oxa-13-prostynoic acid less than 45 mug/ml, activation is seen, while at higher concentrations, inhibition is seen. Different naturally occurring prostaglandins appear to be site-specific. Prostaglandin E(1) gives only activation of the cyclase, while prostaglandin A(1) gives only inhibition of the activated cyclase. When saturating concentrations of prostaglandin E(1) are used to activate adenylate cyclase, no further activation by 7-oxa-13-prostynoic acid can be elicited, indicating that both molecules activate at the same site. The similarity of inhibition constants for both 7-oxa-13-prostynoic acid and prostaglandin A(1) suggests that the mode of binding is the same for both compounds and that they probably inhibit by acting at the same site. The inhibition by 7-oxa-13-prostynoic acid and by prostaglandin A(1) overrides enzyme activation produced by either Escherichia coli enterotoxin, prostaglandin E(1), or sodium fluoride, suggesting that in intestinal adenylate cyclase this site is the primary regulatory site (i.e., primary allosteric effector site) for enzyme activity. These data suggest that sites exist on adenylate cyclase which would allow prostaglandins to serve as the intracellular messengers by which the cell controls its adenylate-cyclase-mediated response to extracellular stimulation, as with hormones.
D000067956:Adenylyl Cyclase Inhibitors; D000262:Adenylyl Cyclases / Q000378:metabolism*; D000818:Animals; D001665:Binding Sites / Q000187:drug effects; D001667:Binding, Competitive; D004768:Enterotoxins / Q000494:pharmacology; D004789:Enzyme Activation / Q000187:drug effects; D004847:Epithelial Cells; D004848:Epithelium / Q000201:enzymology; D004926:Escherichia coli; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology; D066298:In Vitro Techniques; D007413:Intestinal Mucosa / Q000201:enzymology* / Q000378:metabolism; D007700:Kinetics; D011448:Prostaglandin Antagonists; D011453:Prostaglandins / Q000378:metabolism / Q000494:pharmacology*; D011817:Rabbits; D011955:Receptors, Drug / Q000187:drug effects*
D000067956:Adenylyl Cyclase Inhibitors; D004768:Enterotoxins; D005231:Fatty Acids, Unsaturated; D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D011955:Receptors, Drug; D000262:Adenylyl Cyclases